title: 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.
abstract: Neuroblastoma is the most common extracranial solid tumor in childhood. The poor outcomes of patients with high-risk neuroblastoma have encouraged the search for new therapies. In the current study, the effect of the vitamin D analog 1alpha-hydroxyvitamin D2 (1alpha-OH-D2, doxercalciferol) was assessed in a mouse xenograft model of human neuroblastoma. Vitamin D receptor (VDR) expression levels in seven neuroblastoma cell lines were compared using real-time PCR. SK-N-AS cells, which express relatively high levels of VDR, were injected into the flanks of 60 mice. The mice were treated daily via oral gavage for 5 weeks with vehicle (control), 0.15 microg, or 0.3 microg of 1alpha-OH-D2. The animals were then euthanized, and tumors, sera, and kidneys were collected and analyzed. End tumor volumes were significantly smaller in both the 0.15 microg group (712.07 mm3, P = 0.0121) and 0.3 microg group (772.97 mm3, P = 0.0209) when compared to controls (1,681.75 mm3). In terms of toxicity, serum calcium levels were increased but mortality was minimal in both treatment groups. These results were similar to those previously described in the transgenic (LHbeta-Tag) and human xenograft (Y-79) models of retinoblastoma, a related tumor. In vitro cell viability studies of SK-N-AS and NGP cells, which represent two major human neuroblastoma subtypes that differ in their genetic abnormalities as well as their VDR expression levels, show that both are sensitive to calcitriol, the active metabolite of vitamin D3. In conclusion, the present study shows that 1alpha-OH-D2 can inhibit human neuroblastoma growth in vivo with relatively low toxicity. The safety of 1alpha-OH-D2 has been extensively studied; the drug is FDA-approved for the treatment of adult kidney patients, and Phase I/II trials have been conducted in adult oncology patients. There should not be major obstacles to starting Phase I and II clinical trials with this drug in pediatric patients with high-risk neuroblastoma.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6/412 CSC, Madison, WI 53792, USA.
authors.forename: Paul R
authors.initials: PR
authors.lastname: van Ginkel
authors.forename: William
authors.initials: W
authors.lastname: Yang
authors.forename: Marcus M
authors.initials: MM
authors.lastname: Marcet
authors.forename: Clement C
authors.initials: CC
authors.lastname: Chow
authors.forename: Amol D
authors.initials: AD
authors.lastname: Kulkarni
authors.forename: Soesiawati
authors.initials: S
authors.lastname: Darjatmoko
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Lindstrom
authors.forename: Janice
authors.initials: J
authors.lastname: Lokken
authors.forename: Saswati
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Albert
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002118:Calcium / Q000097:blood; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D004872:Ergocalciferols / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental; D009447:Neuroblastoma / Q000188:drug therapy / Q000378:metabolism*; D011897:Random Allocation; D018167:Receptors, Calcitriol / Q000378:metabolism*; D014183:Transplantation, Heterologous
chemical_list: D004872:Ergocalciferols; D018167:Receptors, Calcitriol; C042533:1 alpha-hydroxyergocalciferol; D002118:Calcium